Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Shares of Wells Fargo rose 3.9% after the San Francisco bank’s fourth-quarter profit of $1.43 a share beat expectations of $1 ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback